Product Description
The TY25-CP023 monoclonal antibody is a recombinant, Fc-engineered chimeric version of the original TY25 antibody. The variable domain sequences are identical but the constant region sequences have been switched from Rat IgG2a, kappa to Mouse IgG2a, kappa for use in murine models. Species-matched chimeric antibodies exhibit regulated effector functions-including Fc receptor binding and complement activation-and result in less immunogenicity and formation of anti-drug antibodies (ADAs) than xenogenic antibodies in animal models. This antibody has an effector function competent Fc domain allowing for activation of Fcgamma receptors (FcgammaRs) to trigger antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC) and opsonization to promote target cell depletion. The mouse IgG2a isotype demonstrates strong effector functions due to potent interaction with mFcgammaRIV, which is functionally similar to the FcgammaRIIIa receptor involved in human ADCC. The highly controlled sequence and lack of genetic drift in recombinant antibodies provide more reliable and reproducible results over hybridoma derived antibodies. The TY25-CP023 monoclonal antibody reacts with mouse PD-L2 (programmed death ligand 2) also known as B7-DC or CD273. PD-L2 is a 25 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily. PD-L2 is expressed on monocytes, macrophages and subsets of dendritic cells. PD-L2 binds to its receptor, PD-1, found on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. Engagement of PD-L2 with PD-1 leads to inhibition of TCR-mediated T cell proliferation and cytokine production. The TY25 antibody has been reported to block PD-1 mediated interactions in vivo.
* VAT and shipping costs not included. Errors and price changes excepted
